Similar articles

• Parkinson disease: Gene therapy for Parkinson disease--a hope, or a dream?

  Olanow CW. Olanow CW. Nat Rev Neurol. 2014 Apr;10(4):186-7. doi: 10.1038/nrneurol.2014.45. Epub 2014 Mar 25. Nat Rev Neurol. 2014. PMID: 24662536 No abstract available.
• Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

  Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA. Palfi S, et al. Lancet. 2014 Mar 29;383(9923):1138-46. doi: 10.1016/S0140-6736(13)61939-X. Epub 2014 Jan 10. Lancet. 2014. PMID: 24412048 Clinical Trial.
• A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease.

  Stewart HJ, Fong-Wong L, Strickland I, Chipchase D, Kelleher M, Stevenson L, Thoree V, McCarthy J, Ralph GS, Mitrophanous KA, Radcliffe PA. Stewart HJ, et al. Hum Gene Ther. 2011 Mar;22(3):357-69. doi: 10.1089/hum.2010.142. Epub 2011 Feb 10. Hum Gene Ther. 2011. PMID: 21070114
• Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier?

  Price RJ, Fisher DG, Suk JS, Hanes J, Ko HS, Kordower JH. Price RJ, et al. Mov Disord. 2019 Sep;34(9):1279-1282. doi: 10.1002/mds.27675. Epub 2019 Mar 25. Mov Disord. 2019. PMID: 30908781 Free PMC article. Review. No abstract available.
• Herpes simplex virus vectors for Parkinson's disease.

  Latchman DS. Latchman DS. Int Rev Neurobiol. 2003;55:223-41. doi: 10.1016/s0074-7742(03)01010-9. Int Rev Neurobiol. 2003. PMID: 12968539 Review. No abstract available.